gefitinib has been researched along with aspirin in 12 studies
Studies (gefitinib) | Trials (gefitinib) | Recent Studies (post-2010) (gefitinib) | Studies (aspirin) | Trials (aspirin) | Recent Studies (post-2010) (aspirin) |
---|---|---|---|---|---|
5,231 | 566 | 2,919 | 48,947 | 6,817 | 13,778 |
Protein | Taxonomy | gefitinib (IC50) | aspirin (IC50) |
---|---|---|---|
Prostaglandin G/H synthase 1 | Bos taurus (cattle) | 0.35 | |
Integrin beta-3 | Homo sapiens (human) | 5 | |
Prostaglandin G/H synthase 1 | Ovis aries (sheep) | 0.8252 | |
Seed linoleate 13S-lipoxygenase-1 | Glycine max (soybean) | 1.375 | |
Integrin alpha-IIb | Homo sapiens (human) | 5 | |
Prostaglandin G/H synthase 1 | Homo sapiens (human) | 2.271 | |
Substance-P receptor | Cavia porcellus (domestic guinea pig) | 2.4 | |
Prostaglandin G/H synthase 2 | Homo sapiens (human) | 2.15 | |
Urotensin-2 receptor | Rattus norvegicus (Norway rat) | 0.3 | |
4-aminobutyrate aminotransferase, mitochondrial | Rattus norvegicus (Norway rat) | 2.4 | |
Gamma-aminobutyric acid receptor subunit alpha-1 | Rattus norvegicus (Norway rat) | 0.35 | |
Prostaglandin G/H synthase 2 | Ovis aries (sheep) | 2.4081 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 5 (41.67) | 29.6817 |
2010's | 7 (58.33) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
Lombardo, F; Obach, RS; Waters, NJ | 1 |
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
Ekins, S; Williams, AJ; Xu, JJ | 1 |
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Abdel-Maksoud, MS; Ali, EMH; Oh, CH | 1 |
Kanazawa, S; Kinoshita, Y; Komiyama, Y; Muramatsu, M; Nomura, S; Yamaguchi, K | 1 |
Becker, JC; Berdel, WE; Brandts, C; Domschke, W; Fujimori, T; Ilea, AM; Müller-Tidow, C; Pohle, T; Serve, H; Stolte, M; Tickenbrock, L; Tidow, N | 1 |
Kubo, K | 1 |
Grubbs, CJ; Juliana, MM; Lubet, RA; Steele, VE | 1 |
3 review(s) available for gefitinib and aspirin
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Thieno[2,3-d]pyrimidine as a promising scaffold in medicinal chemistry: Recent advances.
Topics: Anti-Infective Agents; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Chemistry, Pharmaceutical; Humans; Inflammation; Neoplasms; Pyrimidines; Structure-Activity Relationship | 2019 |
[Drug-induced pulmonary edema].
Topics: Amiodarone; Anti-Arrhythmia Agents; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Aspirin; Diagnosis, Differential; Drug-Related Side Effects and Adverse Reactions; Gefitinib; Glucocorticoids; Humans; Immunosuppressive Agents; Norepinephrine; Pulmonary Edema; Quinazolines; Respiration, Artificial; Risk Factors | 2007 |
1 trial(s) available for gefitinib and aspirin
Article | Year |
---|---|
Aspirin reduces adverse effects of gefitinib.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Aspirin; Carcinoma, Non-Small-Cell Lung; Drug Interactions; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; P-Selectin; Platelet Activation; Platelet Aggregation Inhibitors; Prospective Studies; Quinazolines; Thromboxane B2 | 2006 |
8 other study(ies) available for gefitinib and aspirin
Article | Year |
---|---|
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Acetylsalicylic acid enhances antiproliferative effects of the EGFR inhibitor gefitinib in the absence of activating mutations in gastric cancer.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Aspirin; Blotting, Western; Cell Survival; Drug Synergism; Drug Therapy, Combination; ErbB Receptors; Female; Gefitinib; Gene Expression Profiling; Humans; Middle Aged; Mutation; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Stomach Neoplasms; Tumor Cells, Cultured | 2006 |
Screening agents for preventive efficacy in a bladder cancer model: study design, end points, and gefitinib and naproxen efficacy.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Aspirin; Cyclooxygenase Inhibitors; Disease Models, Animal; Drug Screening Assays, Antitumor; Female; Gefitinib; Naproxen; Quinazolines; Rats; Rats, Inbred F344; Research Design; Resveratrol; Stilbenes; Urinary Bladder Neoplasms | 2010 |